Ai In Biomanufacturing Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

AI in biomanufacturing refers to the integration of machine learning, deep learning, and data-driven automation into the production of biologics, vaccines, cell and gene therapies, and industrial bioproducts. The global market reached approximately $4.6 billion in 2025 and is currently estimated at $5.52 billion in 2026, forecast to grow to approximately $13.7 billion by 2031. Adoption is concentrated among large biopharma manufacturers, contract development and manufacturing organizations (CDMOs), and emerging biotech firms seeking to shorten development timelines and reduce batch failures.

• •Market reached approximately $4.6 billion in 2025, currently estimated at $5.52 billion in 2026
• •Projected to reach approximately $13.7 billion by 2031 at a 20.0% CAGR
• •Primary adopters include large biopharma manufacturers, CDMOs, and emerging biotech firms

Rising global demand for biologics, monoclonal antibodies, and cell and gene therapies is pushing manufacturers to scale up production while maintaining stringent quality standards. AI tools help address these pressures by improving yield, reducing deviation rates, and enabling continuous-manufacturing paradigms. Additionally, growing data availability from sensors and PAT (Process Analytical Technology) systems, combined with cost-competitive cloud computing, is making AI deployment economically viable for both large and mid-sized producers.

• •Rising demand for biologics, monoclonal antibodies, and cell and gene therapies
• •AI tools improve yield, reduce deviation rates, and enable continuous manufacturing
• •Growing data availability from sensors and PAT systems
• •Cost-competitive cloud computing making AI deployment economically viable

The market segments by component (software platforms, services, and hardware), application (upstream processing, downstream processing, and quality assurance), and end user (biopharma companies, CDMOs, and academic/research institutes). North America leads in adoption due to a dense concentration of biologics manufacturers and digital health infrastructure, while Europe follows closely, supported by strong regulatory frameworks and public-private innovation funding. Asia-Pacific is the fastest-growing region, driven by expanding biosimilar production in China, India, and South Korea.

• •Component: software platforms, services, and hardware
• •Application: upstream processing, downstream processing, and quality assurance
• •End user: biopharma companies, CDMOs, and academic/research institutes
• •North America leads adoption; Europe follows; Asia-Pacific is the fastest-growing region

What are the recent trends and outlook?

The next phase of growth is expected to center on generative AI for experimental design, foundation models trained on multi-modal bioprocess data, and tighter integration with robotic lab and pilot-plant systems. Foundation models and digital twins of entire manufacturing lines are moving from pilots to early commercial deployment. As regulators continue to clarify expectations around AI validation, vendors that can demonstrate model robustness, traceability, and compliance will be best positioned to capture share through 2031.

• •Generative AI for experimental design and foundation models on multi-modal bioprocess data
• •Tighter integration with robotic lab and pilot-plant systems
• •Foundation models and digital twins moving from pilots to early commercial deployment
• •Vendors demonstrating model robustness, traceability, and compliance best positioned through 2031